‍NovaScan is revolutionizing cancer assessment and treatment. The novel modality, backed by 24 patents, uses bioelectrical impedance spectroscopy combined with machine learning to precisely detect cancer, assess its state, guide its removal, and deliver immuno-oncology therapies.

NovaScan provides an objective and quantitative measure with best-in-class sensitivity and specificity. It has multiple embodiments (biopsy, margin, drug delivery) and can work both in-vivo and ex-vivo. www.novascaninc.com